It was analyzed that Hanmi Pharmaceutical's IMD 'Esomezol' which entered the U.S. market late last year, is recording poor sales
It was analyzed that Hanmi Pharmaceutical's IMD 'Esomezol' (anti-ulcer agent) which entered the U.S. market late last year, is recording poor sales.
On July 4, according to the business analysis report of Daewoo Securities Company, sales of Esomezol in the U.S. falls short of its initial expecta...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
